Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
May 20, 2021 08:00 ET
|
Replimune Group Inc
Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma ...
Replimune Appoints Tanya Lewis as Chief Development Operations Officer
May 10, 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today...
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma
May 05, 2021 07:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today...
Replimune to Host Virtual Investor Event on June 3, 2021
April 28, 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today...
Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
April 21, 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting
April 12, 2021 16:01 ET
|
Replimune Group Inc
Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2 Increased infiltration of CD8+ T cells and PD-L1 expression for patients dosed with RP1 in...
Replimune to Present at the American Association for Cancer Research Annual Meeting 2021
March 11, 2021 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune to Present at Three Upcoming Investor Conferences
March 04, 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
February 04, 2021 08:00 ET
|
Replimune Group Inc
RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across...